MGI PHARMA Issues Statement

MINNEAPOLIS--(Business Wire)--MGI PHARMA, INC. (NASDAQ:MOGN) a biopharmaceutical company focusedin oncology and acute care, today stated that its board of directorshas authorized management to evaluate possible strategic alternatives.To assist in this process, the company retained the services of LehmanBrothers, who is acting as its exclusive financial advisor. There canbe no assurance that a strategic transaction will be pursued orconsummated, and the company indicated that its strategy is yieldingstrong operating and financial performance. Contrary to statements recently reported, it is the company'spolicy not to comment on rumors and speculation regarding its reviewof possible strategic alternatives. In keeping with that policy, thecompany will not publicly disclose further information regarding thestatus of its evaluation until the process has been completed. About MGI PHARMA MGI PHARMA, INC. is a biopharmaceutical company focused inoncology and acute care that acquires, researches, develops, andcommercializes proprietary products that address the unmet needs ofpatients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride)Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer

(polifeprosan 20 with carmustine implant) in the United States. TheCompany directly markets its products in the U.S. and collaborateswith partners to reach international markets. For more informationabout MGI PHARMA, please visit www.mgipharma.com. This news release contains certain "forward-looking" statementswithin the meaning of the Private Securities Litigation Reform Act of1995. Forward looking statements typically are preceded by words suchas "believes," "expects," "anticipates," "intends," "will," "may,""should," or similar expressions. These forward-looking statements arenot guarantees of MGI PHARMA's future performance and involve a numberof risks and uncertainties that may cause actual results to differmaterially from the results discussed in these statements. Factorsthat might cause MGI PHARMA's results to differ materially from thoseexpressed or implied by such forward-looking statements include, butare not limited to, those risks and uncertainties detailed from timeto time in MGI PHARMA's filings with the Securities and ExchangeCommission including its most recently filed Form 10-Q or 10-K. MGIPHARMA undertakes no duty to update any of these forward-lookingstatements.MGI PHARMA, INC.Timothy J. Smith, 952-406-3100IR@mgipharma.comCopyright Business Wire 2007